24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
ENZALIEVA 40MG is an Capsules medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | ENZALIEVA 40MG |
|---|---|
| Composition | Enzalutamide Capsules 40mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsules |
| Packaging | Strip (4 x 28 cap) |
| Country of Origin | India |
ENZALIEVA 40MG (Enzalutamide Capsules 40mg) is a widely used Capsules medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is a prescription anticancer medicine containing Enzalutamide 40 mg, a next-generation androgen receptor inhibitor used for the treatment of advanced prostate cancer. It is specifically designed to help slow the growth and spread of prostate cancer cells by blocking the effects of male hormones, known as androgens, that fuel cancer progression.
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Many prostate cancer cells depend on testosterone and other androgens for survival and growth. Even after treatments that lower testosterone levels, cancer cells may continue to grow by activating androgen receptors. ENZALIEVA 40 MG helps overcome this challenge by directly blocking androgen receptor signaling, thereby reducing the ability of cancer cells to multiply and spread.
Enzalutamide belongs to a class of medicines known as Androgen Receptor Inhibitors. Unlike conventional hormone therapies that primarily reduce testosterone production, Enzalutamide works by preventing androgen receptors from receiving hormonal signals. This dual approach helps provide more effective disease control in advanced stages of prostate cancer.
ENZALIEVA 40 MG is commonly prescribed for:
The medicine may be used as part of a comprehensive cancer treatment plan developed by an oncologist based on the patient's medical condition, disease stage, and treatment history.
Manufactured according to stringent pharmaceutical quality standards, ENZALIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Enzalutamide therapy typically require regular monitoring, including blood pressure assessments, liver function evaluations, neurological monitoring, and routine clinical follow-up to ensure safe and effective treatment.
Due to its targeted mechanism of action and proven clinical benefits, ENZALIEVA 40 MG has become an important treatment option in modern prostate cancer care worldwide.
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is primarily used for the treatment and management of advanced prostate cancer.
The medicine is widely prescribed for patients whose prostate cancer continues to progress despite testosterone-lowering therapies.
Enzalutamide helps delay disease progression in patients without detectable metastases.
The medicine may be used in combination treatment strategies for metastatic hormone-sensitive disease.
Doctors frequently prescribe Enzalutamide to help control advanced-stage prostate cancer.
The medicine may be recommended when prostate cancer returns after previous treatments.
Enzalutamide plays an important role in targeted hormone-based cancer treatment.
The medicine helps delay cancer progression and improve treatment outcomes.
Enzalutamide belongs to a class of medicines known as Androgen Receptor Inhibitors.
ENZALIEVA works by:
This targeted action helps reduce the ability of cancer cells to respond to hormones that promote their growth.
Like all medicines, ENZALIEVA 40 MG may cause side effects in some patients. The occurrence and severity of side effects vary among individuals.
Weakness and tiredness are among the most commonly reported side effects.
Patients may experience episodes of warmth, sweating, or flushing.
The medicine may increase blood pressure in some individuals.
Musculoskeletal discomfort may occur during treatment.
Some patients may experience headaches.
Lightheadedness or dizziness may occur occasionally.
Appetite changes may affect nutritional intake.
Generalized weakness may develop during therapy.
Some individuals may experience difficulty sleeping.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) should always be determined by a qualified oncologist.
The severity and progression of prostate cancer influence treatment recommendations.
Doctors may adjust therapy according to clinical effectiveness and patient tolerance.
Existing health conditions may influence treatment decisions.
Drug interactions may require dosage modifications.
Individual patient factors contribute to treatment planning.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant women should avoid handling damaged capsules unless specifically instructed by healthcare professionals.
It is primarily used for the treatment of advanced prostate cancer, including metastatic and castration-resistant prostate cancer.
Enzalutamide is a targeted hormonal anticancer medicine that blocks androgen receptor signaling in prostate cancer cells.
No. It is a targeted hormonal therapy and works differently from traditional chemotherapy medicines.
It blocks the action of male hormones that promote prostate cancer growth, helping slow disease progression.
Yes. Fatigue is one of the most commonly reported side effects.
Yes. Blood pressure checks, clinical evaluations, and routine monitoring are important throughout treatment.
Yes. Many patients receive Enzalutamide as part of long-term prostate cancer management under medical supervision.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and prostate cancer treatment.